Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3270)
All Articles published online
|
Sep 21, 2007 (publication date) through Apr 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bluethner T, Niederhagen M, Caca K, Serr F, Witzigmann H, Moebius C, Mossner J, Wiedmann M. Inhibition of histone deacetylase for the treatment of biliary tract cancer: A new effective pharmacological approach. World J Gastroenterol 2007; 13(35): 4761-4770 [PMID: 17729398 DOI: 10.3748/wjg.v13.i35.4761] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i35/4761.htm |
| Number | Citing Articles |
| 1 |
Xiangbing Meng, Pavla Brachova, Shujie Yang, Zhi Xiong, Yuping Zhang, Kristina W. Thiel, Kimberly K. Leslie, Andrei L. Gartel. Knockdown of MTDH Sensitizes Endometrial Cancer Cells to Cell Death Induction by Death Receptor Ligand TRAIL and HDAC Inhibitor LBH589 Co-Treatment. PLoS ONE 2011; 6(6): e20920 doi: 10.1371/journal.pone.0020920
|
| 2 |
Li-Ning Xu, Xin Wang, Sheng-Quan Zou. Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines. World Journal of Gastroenterology 2008; 14(16): 2578-2581 doi: 10.3748/wjg.14.2578
|
| 3 |
Marcus Wiedmann, Helmut Witzigmann, Joachim Mössner. Clinical Hepatology. 2010; : 1519 doi: 10.1007/978-3-642-04519-6_62
|
| 4 |
Huiling Wang, Caixia Li, Zhixiang Jian, Yingliang Ou, Jinrui Ou, Jin Q. Cheng. TGF-β1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4. PLOS ONE 2015; 10(10): e0136703 doi: 10.1371/journal.pone.0136703
|
| 5 |
Wenlin Shao, Joseph D. Growney, Yun Feng, Gregory O'Connor, Minying Pu, Wenjing Zhu, Yung‐Mae Yao, Paul Kwon, Stephen Fawell, Peter Atadja. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T‐cell lymphoma models: Defining molecular mechanisms of resistance. International Journal of Cancer 2010; 127(9): 2199 doi: 10.1002/ijc.25218
|
| 6 |
Vikrant Rai, Chandra Boosani, Devendra Agrawal. The promising role of epigenetic mediators and microRNAs in the early diagnosis of cholangiocarcinoma (Review). World Academy of Sciences Journal 2019; doi: 10.3892/wasj.2019.18
|
| 7 |
Maria Graziella Catalano, Mariateresa Pugliese, Eleonora Gargantini, Cristina Grange, Benedetta Bussolati, Sofia Asioli, Ornella Bosco, Roberta Poli, Alessandra Compagnone, Andrea Bandino, Franco Mainini, Nicoletta Fortunati, Giuseppe Boccuzzi. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. International Journal of Cancer 2012; 130(3): 694 doi: 10.1002/ijc.26057
|
| 8 |
Peter Atadja. Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges. Cancer Letters 2009; 280(2): 233 doi: 10.1016/j.canlet.2009.02.019
|
| 9 |
Eric Sanchez, Jing Shen, Jeffrey Steinberg, Mingjie Li, Cathy Wang, Benjamin Bonavida, Haiming Chen, Zhi-Wei Li, James R. Berenson. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leukemia Research 2011; 35(3): 373 doi: 10.1016/j.leukres.2010.06.026
|
| 10 |
Shabir Ahmad Ganai. Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance. Archives of Pharmacal Research 2015; doi: 10.1007/s12272-015-0673-9
|
| 11 |
Antonino Grassadonia, Pasquale Cioffi, Felice Simiele, Laura Iezzi, Marinella Zilli, Clara Natoli. Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers 2013; 5(4): 919 doi: 10.3390/cancers5030919
|
| 12 |
Lubna Wasim, Madhu Chopra. Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells. Biomedicine & Pharmacotherapy 2016; 84: 1393 doi: 10.1016/j.biopha.2016.10.057
|
| 13 |
Joana N.R. Dias, Sandra I. Aguiar, Diane M. Pereira, Ana S. André, Lurdes Gano, João D.G. Correia, Belmira Carrapiço, Barbara Rütgen, Rui Malhó, Conceição Peleteiro, João Goncalves, Cecília M.P. Rodrigues, Solange Gil, Luís Tavares, Frederico Aires-da-Silva. The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma. Oncotarget 2018; 9(47): 28586 doi: 10.18632/oncotarget.25580
|
| 14 |
Daniel H. Ahn, Milind Javle, Chul W. Ahn, Apurva Jain, Sameh Mikhail, Anne M. Noonan, Christina Wu, Rachna T. Shroff, James L. Chen, Tanios Bekaii‐Saab. Next‐generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer 2016; 122(23): 3657 doi: 10.1002/cncr.30247
|
| 15 |
Martin Haefner, Thilo Bluethner, Manuel Niederhagen, Christian Moebius, Christian Wittekind, Joachim Mossner, Karel Caca, Marcus Wiedmann. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World Journal of Gastroenterology 2008; 14(23): 3681-3692 doi: 10.3748/wjg.14.3681
|
| 16 |
Morgan J. Homan, Andrea Franson, Karthik Ravi, Holly Roberts, Manjunath P. Pai, Cai Liu, Miao He, Aleksas Matvekas, Carl Koschmann, Bernard L. Marini. Panobinostat penetrates the blood–brain barrier and achieves effective brain concentrations in a murine model. Cancer Chemotherapy and Pharmacology 2021; 88(3): 555 doi: 10.1007/s00280-021-04313-2
|